No Data
October 25th buyback collection | HSBC Holdings, AIA and others have successively repurchased, with HSBC Holdings spending 65.7889 million Hong Kong dollars.
According to the disclosure documents released by hkex on October 28, hsbc holdings (00005.HK), aia (01299.HK), and others repurchased shares. ① hsbc holdings (00005.HK) repurchased 0.96 million ordinary shares on October 24, involving 65.7889 million Hong Kong dollars, with a repurchase price per share ranging from 68.75 Hong Kong dollars to 68.2 Hong Kong dollars. ② aia (01299.HK) repurchased 0.9856 million ordinary shares on October 25, involving 62.3662 million Hong Kong dollars, with a repurchase price per share ranging from 64.3
October 21st Buyback Compilation | hsbc holdings, aia and others have successively repurchased, with hsbc holdings spending 0.102 billion Hong Kong dollars.
According to the disclosure documents released by hkex on October 22, hsbc holdings (00005.HK) and aia (01299.HK) repurchased shares. ① Hsbc holdings (00005.HK) repurchased 1.484 million shares of common stock on October 18, involving 0.102 billion Hong Kong dollars, with the repurchase price per share ranging from 69.1 Hong Kong dollars to 68.4 Hong Kong dollars. ② Aia (01299.HK) repurchased 1.002 million shares of common stock on October 21, involving 62.3921 million Hong Kong dollars, with the repurchase price per share ranging from 62.9 Hong Kong dollars.
On October 21st, Gaxca-B (01167.HK) spent 0.123 million Hong Kong dollars to repurchase 0.0654 million shares.
Gelonghui October 21st | Jakes-B (01167.HK) announced, on October 21, 2024, the company spent 0.123 million Hong Kong dollars to repurchase 0.0654 million shares.
Jacobio Pharmaceuticals' Cancer Drug Gets Orphan Drug Designation From European Medicines Agency
October 18th buyback collection | HSBC Holdings, AIA and others have repurchased, with HSBC Holdings spending 0.101 billion Hong Kong dollars.
According to hkex disclosure on October 21, hsbc holdings (00005.HK), aia (01299.HK), and others repurchased shares. ① hsbc holdings (00005.HK) repurchased 1.4864 million shares of common stock on October 17, involving an amount of 0.101 billion Hong Kong dollars, with a repurchase price per share ranging from 68.55 Hong Kong dollars to 67.55 Hong Kong dollars. ② aia (01299.HK) repurchased 0.9878 million shares of common stock on October 18, involving an amount of 61.8387 million Hong Kong dollars, with a repurchase price per share ranging from 63.
Jaccard-B (01167.HK): Golirex approved for orphan drug therapy indication for pancreatic cancer in europe.
Gecoris-B (01167.HK) announced on October 21 that its main research and development KRAS G12C inhibitor Glecirasib was granted orphan drug therapy designation for pancreatic cancer by the European Medicines Agency. Pancreatic cancer is a highly malignant tumor, with patients currently lacking effective standard treatment options. The overall five-year survival rate for advanced pancreatic cancer is only 3.1%. Previously, the indication for Glecirasib in pancreatic cancer received orphan drug therapy designation in the USA by the US Food and Drug Administration and breakthrough therapy designation by the National Medical Products Administration's Drug Evaluation Center in China.
No Data
No Data